Key result
In patients with CAD and type 2 diabetes, platelet aggregation increased at the end of the 24-hour aspirin dosing interval.
Why the study?
Does the antiplatelet effect of aspirin decline during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes?
Observational (n=47)
Does the antiplatelet effect of aspirin decline during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes?
Patients with CAD and type 2 diabetes experience a significant decline in aspirin-induced platelet inhibition at the end of a 24-hour dosing interval.
Answers are grounded in this paper and cite their sources.
Declining aspirin effect over 24h in CAD+T2D warrants dosing caution; leaves open whether adjusted regimens improve outcomes.
Reduced antiplatelet effect of aspirin has been reported in patients with type 2 diabetes, and recent studies suggest that once-daily aspirin provides insufficient platelet inhibition. We investigated if the effect of aspirin declined during the 24-hour dosing interval in patients with coronary artery disease and type 2 diabetes, and whether this correlated with increased platelet turnover. Furthermore, the intra-individual variation in platelet aggregation was determined during a 28-day period. We included 47 patients with coronary artery disease and type 2 diabetes treated with aspirin 75 mg daily. Blood samples were obtained 1 and 24 hours after aspirin intake, and this was repeated three times with a 2-week interval between each visit. Platelet aggregation was evaluated by impedance aggregometry (Multiplate® Analyzer) using arachidonic acid (1.0 mM) and collagen (3.2 µg/ml) as agonists. Markers of platelet turnover were measured by flow cytometry. Compliance was confirmed by serum thromboxane B2. Platelet aggregation levels measured 1 and 24 hours after aspirin intake were compared using the mean of 1- and 24-hour measurements at the three study visits. The difference in platelet aggregation was 70 ± 97 AU × min (p < 0.0001) when using arachidonic acid as agonist and 33 ± 76 AU × min (p = 0.01) when using collagen. Markers of platelet turnover correlated positively, though not significantly, with residual platelet aggregation 24 hours after aspirin intake (p values 0.06 and 0.07). Median intra-individual variation of platelet aggregation was 9-16%. Patients with coronary artery disease and type 2 diabetes had increased platelet aggregation at the end of the 24-hour aspirin dosing interval. Platelet turnover did not correlate significantly with residual platelet aggregation, although a trend was observed. The intra-individual variation of platelet aggregation after aspirin intake was low.
No takes yet. Share an insight, caveat, or question.
Christensen et al. (2014) conducted an observational in Coronary artery disease and type 2 diabetes (n=47). Aspirin vs. 1 hour vs 24 hours post-intake was evaluated on Difference in platelet aggregation 1 and 24 hours after aspirin intake (arachidonic acid agonist) (MD 70, p=<0.0001). In patients with CAD and type 2 diabetes, platelet aggregation increased at the end of the 24-hour aspirin dosing interval.
Synapse has enriched 10 related papers. Consider them for comparative context: